Moderna(US:MRNA) Financial Modeling Prep·2026-02-12 11:00Core Viewpoint - Moderna Inc. is facing significant challenges, particularly with its mRNA flu vaccine, which has impacted its financial outlook and stock performance [2][5]. Financial Performance - Analysts predict an earnings per share (EPS) loss of $2.60 for the upcoming quarterly earnings, with projected revenue of $624 million [1][6]. - The company has a negative P/E ratio of -5.07, indicating current earnings struggles, while its price-to-sales ratio of 7.13 suggests investor confidence in its sales potential [3]. - Moderna's enterprise value to sales ratio stands at 6.95, reflecting a valuation perspective that still sees potential in the company's sales capabilities [3]. Financial Health - Moderna exhibits a low debt-to-equity ratio of 0.079, indicating conservative debt usage [4][6]. - The company has a strong current ratio of 3.93, suggesting good short-term financial health and the ability to cover current liabilities with assets [4][6]. - However, the negative earnings yield of -19.72% highlights ongoing profitability challenges [4]. Regulatory Challenges - The FDA's refusal to review Moderna's application for its new mRNA flu vaccine has resulted in a nearly 10% drop in the company's stock [2][6]. - Despite the FDA's decision, no safety or efficacy issues were raised, and Moderna is actively seeking a Type A meeting to address the concerns related to trial design [2]. Strategic Initiatives - Moderna is continuing its vaccine development efforts and is seeking approvals in the European Union, Canada, and Australia [5].